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Summary
Colorectal cancer is a relatively common tumor with incidence that has been increasing 
during recent decades. Despite the rapid advances in treatment of colorectal cancer, the best 
way to combine and sequence all available drugs to optimize treatment is not yet established. 
The majority of cytotoxic drugs used in therapy of colorectal cancer have a dose related effect 
and narrow therapeutic index. Hence, dosing of cytotoxic drugs is considered very important. 
Current modalities for therapy and dose selection give restricted possibilities to equalise inter-in-
dividual variations which are dependent on physiological, genetic and environmental factors. In 
this article, an overview of current possibilities of personalized medicine in therapy of colorectal 
cancer is presented. This includes review of the most important gene polymorphisms important 
for safety and efficacy of cytotoxic therapy in colorectal cancer, and evaluation of their impor-
tance for the current clinical practice. Despite raising knowledge, providing individual treatment 
with low toxicity and significant benefits is still an unsolved problem. Reasons for this are the 
lack of knowledge on distribution of these polymorphisms in the population, importance of 
non-genetic factors, price of genetic testing and still limited data from controlled clinical trials 
confirming the clinical usefulness of pharmacogenetic testing. Although the initial costs of cancer 
management and personalized medicine may be high, in the future they may result in significant 
benefits from both a clinical and economical perspective. 
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Background
Colorectal cancer is a relatively common tumor with incidence that has been 
increasing during recent decades, and the lifetime risk for colorectal cancer in indu-
strialized countries is about 5% [1]. The last 5 to 10 years have seen unprecedented 
advances in the treatment of colorectal cancer. Therapeutic strategies involve seve-
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ral different classes of drugs with significant anti-tumor activity in colorectal can-
cer: cytotoxic therapy which includes 5-fluorouracil, capecitabine (oral precursor of 
5-fluorouracil), irinotecan and oxaliplatin, and targeted therapy which includes be-
vacizumab, aflibercept, regorafenib, cetuximab and panitumumab [2]. Despite the 
rapid pace of clinical research, the best way to combine and sequence all of these 
drugs to optimize treatment is not yet established.
The majority of cytotoxic drugs have a dose related effect and narrow therapeu-
tic index. Hence dose selection is considered very important. Even small dose vari-
ations can lead to significant toxicity in some patients, and to hypodosing in others. 
There is an important inter-individual variability in the capacity of drug metaboli-
sm and elimination [3]. The choice of therapy is still based on standard clinical and 
pathological parameters represented by Dukes and TNM (Tumor Node Metastasis) 
grading systems. The dose is mostly chosen based on age, height and body mass by 
calculation of BSA (Body Surface Area) [4,5]. However, this gives restricted possibi-
lities to equalise inter-individual variations which are dependent on physiological, 
genetic and environmental factors (drug-drug interactions, drug-food interactions). 
The influence of genetic factors on response variability is far greater than sex, age 
or interactions with other drugs. The distribution frequency of correct responses 
to drug usage in a population is far from normal distribution, which means that 
the presence of treatment non-responders and over-responders (increased toxicity) 
is much more common than has been assumed so far [6]. The clinical problems 
that arise from inter-individual variability in drug metabolism are mostly related 
to of toxic effects of cytotoxic drugs, mainly affecting hair growth, gastrointestinal 
system and bone marrow, but also include resistance to therapy involving various 
mechanisms.
Personalised cancer medicine
Personalised medicine is a new concept arising from the need for more rational 
and effective treatment with less adverse reactions. It is based on the combination of 
therapeutic drug monitoring (TDM) and genotyping with the objective to evaluate 
metabolic capacity of the host and/or the characteristics of the tumor [7]. Cytotoxic 
anticancer drugs fit many of the criteria commonly defined as prerequisites for uti-
lising TDM approaches. Firstly, the extent of inter-individual pharmacokinetic (PK) 
variability exhibited is large in the majority of cases. This large inter-individual 
PK variability is likely to be related to genetic differences as well as variations in 
the functional status of the cancer patients. Furthermore, relationships have been 
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described between plasma concentrations and pharmacodynamic (PD) end-points 
such as percentage decrease in neutrophil counts between pre-treatment and nadir 
values [8]. Genetic factors contribute to the phenotype of drug response. A signifi-
cant proportion of variability in drug response can be attributed to genetic factors 
through modulation of drug PKs and/or PD. So, the rationale behind pharmacoge-
netic studies is to investigate genes encoding drug transporters, drug-metabolising 
enzymes and drug targets that can predict the usefulness of a particular drug so as 
to increase the number of responders and decrease the number of subjects affected 
by adverse drug reactions. Nevertheless, the sources of variability in drug response 
are multifactorial and apart from genetics, factors such as pathophysiology, envi-
ronment, diet, drug–drug interactions, drug allergies, medication errors and poor 
compliance, may all have a profound impact on PKs and/or PDs, thereby affecting 
therapeutic outcome
Pharmacogenetics is not only important for targeted drugs which effectiveness 
is often dependent upon a genetic mutation. Inter-individual differences in toxici-
ty and response are observed in practically all available anticancer treatment regi-
mens. Identification of subgroups of patients which differ in their prognosis and 
response to treatment could be helpful to identify the best available therapy for 
individual patient. 
The first studies on pharmacogenetics and colorectal cancer outcomes were con-
ducted and published approximately 20 years ago [9]. Since then, many possible 
biodeterminants have been studied with many expectations, but the final step of cli-
nical validation has remained an unmet objective for almost all putative biomarkers 
[10]. Consequently, providing individual treatment with low toxicity and significant 
benefit is still an unsolved problem. Reasons for this are the lack of knowledge on 
distribution of these polymorphisms in the population, importance of non-genetic 
factors, price of genetic testing and still limited data from controlled clinical trials 
confirming the clinical usefulness of pharmacogenetic testing. 
Important gene polymorphisms in cytoxic colorectal cancer therapy
Althought significant research on polymorphisms important for the metabolism 
of cytotoxic drugs has been done, the translation of pharmacogenetic outcomes into 
clinical practice has proved to be surprisingly disappointing, with relatively few 
exceptions. These exeptions include genetic polymorphisms important for the me-
tabolism of fluoropirimidines (5-FU and capecitabine) and irinotecan. 
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Fluoropyrimidines
Fifty years after the first synthesis of 5-FU it is still a standard component of 
adjuvant and palliative therapy having a proven impact on survival time in patients 
with colorectal cancer [11]. Experimental studies have shown that 5-FU is conver-
ted to an active metabolite which is a potent inhibitor of DNA synthesis. It forms 
a complex with thymidylate synthase enzyme and 5,10-methylenetetrahydrofolate 
(CH2THF) cofactor, responsible for the catalytic conversion of deoxyuridine monop-
hosphate to deoxythymidine monophosplate which is a substrate for deoxythymidi-
ne triphosphate necessary for the process of DNA synthesis [12]. Despite significant 
progress in understanding the 5-FU activity mechanisms, the identification of mole-
cular markers potentially clinically useful in predicting 5-FU treatment efficacy and 
toxicity and is still the subject of research. Approximately 10–40% of 5-FU develop 
severe, and sometimes life-threatening, toxicity (neutropenia, nausea, vomiting, se-
vere diarrhoea, stomatitis, mucositis, hand–foot syndrome, and neuropathy) [13]. 
5-FU is the sole anticancer agent for which TDM has been validated in more than 
one randomised trial, in terms of improved therapeutic index [14-16]. Individual 
FU dose adjustment based on pharmacokinetic monitoring resulted in significantly 
improved objective response rate, a trend to higher survival rate, and fewer grade 
3/4 toxicities. Approach that includes both patient’s phenotype and genotype up to 
now Has not been studied and proven useful enough to be translated into every-
day oncology practice. However, testing polymorphisms of 2 enzymes involved in 
fluoropirimidine metabolism have found their way into clinical practice. These two 
enzymes are dyhidropyrimidin dehidrogenase (DPD) and thymdylate syntase (TS).
Dyhidropyrimidin dehidrogenase
5-FU as a prodrug, in order to achieve its intracellular cytotoxic activity, requires 
metabolic activation. Inter-individual variability in the response of patients to 5-FU 
treatment may in fact be associated with a decrease in the activity of enzymes respon-
sible for catabolism of the drug, which will result in an increase in drug concentration 
and longer half-life, and thus an increased risk of serious toxic effects. Dihydropyri-
midine dehydrogenase (DPD) is the rate-limiting enzyme for fluoropyrimidine cata-
bolism and eliminates >80% of administered 5-FU. The activity of DPD is dependent 
upon polymorphisms in the DPYD gene. Its activity is extremely variable in tumoral 
tissue and this variation might make a difference to the efficiency of 5-FU treatment, 
since intratumoral drug concentration is one of the most important factors for the de-
termination of the antitumoral effect [17]. Deficiency in DPD activity, however, leads 
to severe toxicity correlated to 5-FU which may even be fatal. The partial or total lack 
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of this enzyme has, in fact, been associated with severe toxicity (mucositis, granulo-
cytopenia, and neuropathy), and in several cases even death, after 5-FU administra-
tion (18). Partial DPD activity deficiency in the general population is about 5%-10%, 
and its total loss is very rare, about 0.2% [19]. However, it has been estimated that 
23-38% of 5-FU toxicity can be attributed to DPD polymorphysms [20]. The acquired 
uncertain evidence is derived mostly from retrospective clinical studies and suggests 
that low expression of the DPYD gene may be a sensitivity marker in tumour cells for 
fluoropyrimidines and thus allow us to predict the degree of response to treatment. 
However, currently quality clinical data have become available that confirmed the 
predictive value of DPYD expression determination in order to predict the efficacy of 
5-FU therapy in colorectal cancer patients [21]. 
An assay for DPD polymorphisms testing is commercially available as well as 
for TYMS polymorphisms. However, pre-emptive testing is not recommended.
The US Food and Drug Administration (FDA) has added statements to the drug 
labels for 5-fluorouracil and capecitabine that contraindicate use in patients with 
DPD enzyme deficiency. The FDA drug label also warns to use precaution with in-
travenous 5-fluorouracil in these patients. The Dutch Pharmacogenetics Working Group 
has evaluated therapeutic dose recommendations for 5-fluorouracil, capecitabine, 
and tegafur (5-fluorouracil prodrug combined with uracil; not available in United 
States). The Working Group recommends the use of an alternative drug for homozy-
gous carriers of a decreased-activity allele and a reduced dose or alternative drug to 
capecitabine or 5-fluorouracil for heterozygous carriers of a decreased-activity allele 
[22]. Recently, Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihy-
dropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing have been issued 
on dosing recommendations for fluoropyrimidines based on DPYD genotype, reco-
mmending that in heterozygous for high risk alleles the dose of fluoropyrimidines 
should be reduced by 50% and in homozygous instead of fluoropyrimidines alter-
native therapy should be used [23]. 
Tymidilate synthase
TYMS polymorphisms which result in increased expression of the enzyme are 
increasing the risk of 5-FU toxicity and decreasing the therapeutic response. In par-
ticular, TS overexpression has been found to be significantly associated with a low 
response to treatment based on 5-FU, both as adjuvant [24] and metastatic therapy 
[25]. Colorectal cancer patients with low levels of TYMS gene expression had a signi-
ficantly higher rate of response to therapy and longer median survival compared to 
patients with higher TS expression in tumor tissue (leichman-19). Subsequent meta-
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analyses confirmed the importance of TS expression on overall response rate and 
overal survival [26,27]. Available data suggest that high-risk TYMS polymorphisms 
are associated with 1.4-2.4 higher risk for 5-FU toxicity. Still, the positive predic-
tive value of these tests is limited (50%) [28]. There is a need for further analyses 
to allow identification of TYMS transcription regulatory mechanisms including the 
role played by combinations of different genetic variants and their expression vari-
ability in populations. No recommendations have been issued on dosing of fluoro-
pyrimidines by TS phenotype.
Other gene polymorphisms possibly important for fluoropirimidine efficacy 
and toxicity for various enzymes have currently been explored (eg. dihydropyrimi-
dinase, beta-ureidopropionase, methylenetetrahydrofolate reductase), but available 
research data are insufficient for conclusions on their potential clinical usefulness. 
Irinotecan
Irinotecan is a synthetic analogue of a naturally occurring alkaloid, camptot-
hecin. It was first approved for clinical use in Japan in 1994 for the treatment of 
small-cell lung cancer and hematologic malignancies, and then in 1995 in France 
for the treatment of advanced colorectal cancer. Tumour-specific somatic mutations 
and abnormal gene expression have been reported to be associated with irinote-
can therapeutic efficacy and toxicity. However, the available studies do not provide 
unequivocal confirmation that somatic mutations have a significant impact on the 
outcome of irinotecan treatment, which prevents their usage as predictive markers. 
Generally, genetic variations may influence both the pharmacokinetics and phar-
macodynamics of irinotecan [29,30]. 
It is recognised that there is large PK and PD inter-individual variability in pati-
ents receiving irinotecan with limited dependence on dosing based on BSA [31]. PK 
variability is linked to variability in billiary excretion and inherited variations in 
metabolic pathway which controls degradation of irinotecan. 
Uridine diphospate glucoronosyltransferase
The active metabolite of irinotecan, SN-38, is glucuronidated mainly in the liver 
by the uridine diphosphate glucuronosyltransferase enzymes (UGTs), primarily the 
UDP-glycosyltransferase 1 family (UGT1As) isoenzyme, responsible in humans for 
bilirubin conjugation with glucuronic acid. UGTs are one of the most important 
classes of enzyme proteins participating in the coupling reaction phase II of xeno-
biotic metabolism. First evidence from clinical trials on the role of UGT1A1*28 in the 
development of toxicity resulting from administration of irinotecan was published 
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by Ando et al [32]. It is estimated that there are 8-10% homozygous people for this 
allele in the population. Homozygous patients for the UGT1A1*28 allele have incre-
ased risk for severe neutropenia and severe delayed-type diarrhoea after treatment 
with irinotecan [33]. 
Early research and meta-analyses have suggested that the toxic effect of irino-
tecan is dose dependent and that this effect is not likely in patients receiving low 
doses of irinotecan (100-125 mg/m2 weekly). Subsequent meta-analysis showed that 
UGT1A1*29 allele polymorphism is significantly associated with risk of neutrope-
nia in all dose regiments. Still, this risk is significantly higher with higher doses of 
irinotecan ≥250 mg/m2 (RR 7.0, 95%ci 3.10-16.78) as compared to lower doses (80-
145 mg/m2 weekly, RR 2.43, 95%CI 1.34-4.39) [34]. It is still unclear if neutropenia 
prevention would be possible with previous identification of homozygous patients. 
Only 1/10 are homozygous and it is unclear how much of the added risk for neutro-
penia can be attributed to irinotecan, especially in lower dosage. However, some 
studies have shown significant differences in prevalence of severe neutropenia in 
patients homozygous for UGT1A1*28 allele as compared to controls (48% vs 10%, 
respectively), higher hospitalization rate and higher mortality [35]. Subsequent sy-
stematic reviews and meta-analyses are generally supportive of the clinical utility 
of genotyping UGT1A1*28 prior to commencement of irinotecan therapy in order to 
decrease the risk of severe neutropenia and diarrhoea through the pre-emptive dose 
reduction of irinotecan for UGT1A1*28 homozygotes [36,37], and indicate that there 
is unlikely to be an important association between UGT1A1 genotype and overall 
response rate with irinotecan, however, this does not provide direct evidence that 
a dose reduction for UGT1A1*28 homozygous patients will not lead to an important 
reduction in overal response rate [38].
There is still no consensus on the need for dose reduction in homozygous pa-
tients. In conclusion, the clinical utility of pre-emptive UGT1A1*28 allele testing is 
not yet known. One proof-of-concept study has been conducted that showed that 
the maximum tolerated dose of irinotecan in UGT1A1*29 allele homozygous pati-
ents was significantly lower as compared to normal variants (400 mg vs. 840 mg). 
The authors concluded that identification of UGT1A1*28 genotype is useful for iri-
notecan dose individualisation [39]. An assay for UGT1A1 polymorphisms testing 
is commercially available (Invader UGT1A1 Molecular Assay), specifically for testing 
theUGT1A1*1 (wild-type) and the UGT1A1*28 genotype. However, the proposed be-
nefit of testing colorectal cancer patients for UGT1A1 genotype is that the risk for 
adverse drug-related side effects among patients found to be homozygous for the 
UGT1A1*28 genotype can be reduced by lowering their initial and/or subsequent 
doses of irinotecan. The concomitant harm is that a reduction in irinotecan dosage 
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may also reduce the effectiveness of chemotherapy in tumour suppression and long-
term survival [40]. 
There are other gene polymorphisms important for irinotecan metabolism that 
currently being explored (eg. carboxylesterase, topoisomerase-1, aprataxin, etc.) but 
the available data are insufficient for conclusions on their potential clinical usefulness. 
Oxaliplatin
Combination therapy with 5-FU/leucovorin plus oxaliplatin (FOLFOX) is cu-
rrently a standard in treating gastric cancer and colorectal cancer with a 40% positive 
response ratio during first relapse therapy [41]. Despite the efficiency of combined 
therapy, a high percentage of patients show drug resistance to a higher or lower de-
gree, which suggest that the therapeutic efficiency of FOLFOX is characterised by high 
variability. Insufficient intra-tumour concentration of platinum compounds is a cri-
tical factor determining both primary and secondary resistance. Potential platinum 
uptake or influx transporters include copper transporter proteins [42], organic cation 
transporters belonging to the SLC22 family [43] and an undefined cis-configuration 
specific platinum influx transporter (44), in addition to drug transporters facilitating 
the active efflux of platinum compounds including adenosine triphosphate and addi-
tionally adenosine triphosphate (ATP) binding cassette (ABC) multidrug transporters, 
and copper-transporting P-type adenosine triphosphatases (ATPases) [45].Clinical 
studies concerning transporters for platinum derivatives have concentrated on evalu-
ation of the connection between intratumour expression of certain transporters and 
the results of treatment after chemotherapy based on platinum derivatives. In vivo cli-
nical research is required to elucidate the meaning of genetic variability of membrane 
transporters and channels for gene expression and their influence on the pharmaco-
kinetics and effectiveness of oxaliplatin-based therapy.
Other pathways important for oxaliplatin PK and PD are being evaluated (eg. 
glutathione S-transferases, nucleotide excision repair pathway apoptosis regulati-
on). However, available research dana are insufficient for conclusions on their po-
tential clinical usefulness. 
Barriers to the clinical implementation of pharmacogenomics
Although the testing context for pharmacogenetic tests is different from other 
genetic tests, decisions to use any new clinical tests in medical practice will require 
evaluation of not only the benefit linked to improved drug safety and efficacy, but 
also a host of ethical questions. Due to the uncertainties of future developments in 
the field, thoughts on the ethical aspects are somewhat preliminary at this point. 
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However, some aspects of pharmacogenetics are likely to have a potentially pro-
found impact on medical practice, research and on society as a whole. Therefore, 
much thought has been invested in the anticipation of ethical, legal and social as-
pects of pharmacogenetics [46]. A number of other barriers remain with implement-
ing clinical pharmacogenetics, including clinical utility, cost-effectiveness, profes-
sional education, and regulatory and reimbursement issues [47]. The greater the 
barriers to the clinical adoption of pharmacogenetics, the greater the evidence and 
size of the improvement in clinical outcome required. The problem to date is that 
the evidence and importance of most pharmacogenomic associations are not suffi-
cient to overcome the barriers to the clinical implementation. Although long over-
due, many of these potential barriers are now being subjected to closer examination 
and as a result, a framework for successful clinical uptake of pharmacogenomics is 
emerging. 
Conclusion
The purpose of individualized therapy is to choose the most effective treatment 
and the optimal dosage for each patient, while minimizing toxicity and side effects 
of therapy. A limited number of pharmacogenetic markers are identified in colorec-
tal cancer. In most studies they are explored individually which has led to somewhat 
conflicting results. The simultaneous testing of multiple markers predictive of res-
ponse could help to identify more accurately the true role of these polymorphisms 
in colorectal cancer therapy [48]. Although the initial costs of cancer management 
and personalized medicine may be high, in the future they may result in significant 
benefits from both a clinical and economical perspective. 
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Farmakogenetika citotoksičnog liječenja kolorektalnog karicinoma
Rak kolorektuma relativno je čest tumor s rastućom incidencijom zadnjih desetljeća. Unatoč 
brzom napretku u liječenju kolorektalnog raka, još nije jasno na koji način je najbolje kombinirati 
i kojim redoslijedom koristiti dostupne lijekove. Većina citotoksičnih lijekova koji se primjenjuju 
u liječenju kolorektalnog raka imaju učinak ovisan o dozi i malu terapijsku širinu te je određiva-
nje doze lijeka vrlo značajno. Važeći načini izbora terapije i određivanja doze daju ograničene 
mogućnosti ublažavanja interindividualnih varijacija ovisnih o fiziološkim, genetičkim i okoliš-
nim čimbenicima. U ovom članku dan je pregled trenutačnih mogućnosti individualiziranja lije-
čenja kolorektalnog raka. To uključuje pregled najznačajnihih genetskih polimorfizama bitnih za 
sigurnost i učinkovitost citotoksične terapije u liječenju kolorektalnog raka te evaluaciju njihove 
značajnosti za trenutačnu kliničku praksu. Unatoč sve većem znanju, omogućavanje individu-
aliziranog liječenja uz ograničavanje toksičnosti a potenciranje učinkovitosti još je neriješeni 
problem. Razlog za to su manjak znanja o distribuciji polimorfizama u populaciji, važnosti ne-
genetičkih čimbenika, cijena genetičkog testiranja i još uvijek ograničeni podaci iz kontroliranih 
kliničkih studija koji bi potvrdili kliničku korisnost farmakogenetičkog testiranja. Iako inicijalni 
troškovi liječenja kolorektalnog raka i personalizirane medicine mogu biti visoki, u budućnosti 
bi kombinacija ovih pristupa mogla rezultirati značajnim prednostima iz kliničke i ekonomske 
perspektive.
Ključne riječi: kolorektalni rak; farmakogenetika; biomarkeri; personalizirana medicina.
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